M2 macrophage activation in recurrent acute pancreatitis: an explorative analysis of a randomized controlled trial

Rasmus Hagn-Meincke1,2, Mathias E Cook1,2, Jens B Frøkjær2,3

  • 1Centre for Pancreatic Diseases and Mech-Sense, Department of Gastroenterology and Hepatology, Aalborg University Hospital, Aalborg, Denmark.

Abstract

Insights

Naldemedine did not alter M2 macrophage activation markers in recurrent acute pancreatitis (RAP) patients. However, sCD163 levels correlated with disease activity, indicating macrophage activation plays a role in RAP.

Area of Science:

  • Immunology
  • Gastroenterology
  • Clinical Trials

Background:

  • M2 macrophage activation is implicated in pancreatitis, potentially driving progression from recurrent acute pancreatitis (RAP) to chronic disease.
  • Existing evidence is primarily preclinical or cross-sectional, necessitating prospective studies to understand M2 macrophage activation in RAP.

Purpose of the Study:

  • To prospectively investigate the effect of naldemedine on M2 macrophage activation biomarkers (sCD163 and sCD206) in patients with RAP.
  • To explore the association between changes in these biomarkers and clinical measures of disease activity.

Main Methods:

  • An exploratory analysis of a multicenter, randomized, placebo-controlled trial involving patients with RAP.
  • Patients received either naldemedine (0.2 mg daily) or placebo for 12 months.
  • Plasma levels of sCD163 and sCD206 were measured at baseline and trial end, analyzed using linear mixed-effects models and Spearman correlation.

Main Results:

  • Naldemedine treatment did not result in significant changes in mean sCD163 or sCD206 levels compared to placebo.
  • A numerical reduction in RAP frequency was observed with naldemedine, though not statistically significant (HR 0.49, p=0.076).
  • Changes in plasma sCD163 levels positively correlated with the frequency of RAP attacks (rho=0.348, p=0.009) and pain flares (rho=0.318, p=0.017).

Conclusions:

  • Naldemedine did not significantly modulate M2 macrophage activation biomarkers in this RAP cohort.
  • The correlation between sCD163 changes and clinical disease activity underscores the role of macrophage activation in RAP pathophysiology.
  • Further research is needed to clarify the immunomodulatory potential of naldemedine and the precise role of M2 macrophages in pancreatitis progression.

Related Concept Videos

Acute Pancreatitis II: Pathophysiology01:21

Acute Pancreatitis II: Pathophysiology

The pathophysiology of acute pancreatitis centers on injury to pancreatic acinar cells, which initiates a cascade of harmful intracellular events.This injury leads to premature activation of trypsinogen to trypsin in the pancreas. Trypsin then activates other digestive enzymes, such as chymotrypsin, elastase, and phospholipase A2, which begin breaking down pancreatic tissue. The resulting autodigestion causes local inflammation, tissue swelling, hemorrhage, and fat necrosis.Injured acinar cells...
Acute Pancreatitis II: Clinical Manifestations and Management01:30

Acute Pancreatitis II: Clinical Manifestations and Management

Acute pancreatitis presents a complex medical emergency characterized by rapid onset inflammation of the pancreas, demanding timely diagnosis and management to prevent complications. The condition primarily manifests through severe upper abdominal pain that often radiates to the back. This pain intensifies following the consumption of fatty foods. Accompanying symptoms such as nausea, vomiting, abdominal distention, fever, dyspnea, cyanosis, and jaundice can vary in intensity but significantly...
Chronic Pancreatitis II: Pathophysiology01:21

Chronic Pancreatitis II: Pathophysiology

Chronic pancreatitis is a progressive and irreversible inflammation of the pancreas, most often caused by long-term alcohol abuse, but it can also be related to ductal obstruction, smoking, or genetic factors.Chronic pancreatitis occurs when the pancreas is repeatedly exposed to harmful agents like alcohol, smoking, ductal obstruction, or genetic predisposition. These factors lead to the release of toxic metabolites and inflammatory cytokines, sustaining chronic inflammation in the pancreatic...
Chronic Pancreatitis II: Collaborative Care01:29

Chronic Pancreatitis II: Collaborative Care

The management of chronic pancreatitis is multifaceted, involving a comprehensive approach that includes thorough assessment, diagnostic testing, and a variety of management strategies.
Assessment: